EUCTR2007-007265-20-BE进行中（未招募）不适用
A Phase II open label randomized parallel group non comparative trial to assess efficacy and safety of the association of IPH1101 and IL-2 alone and in combination with dacarbazine, in patients with metastatic melanoma
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Male or female aged over 18 years,
- •2) Histologically confirmed diagnosis of melanoma,
- •3) Stage IV disease or unresectable stage III c (AJCC ),
- •4) Measurable disease according to modified RECIST criteria defined as at least 1 malignant lesion that could be accurately and serially measured in at least 1 dimension and for which the greatest diameter is > or = 10 mm as measured by spiral computed tomography (CT) scan or magnetic resonance imaging (MRI), or > or = 20 mm with conventional techniques. A caliper can be used for the measurement of superficial cutaneous metastases which are > or = 10 mm;
- •5) Patient who has never been treated by chemotherapy previously,
- •6) ECOG performance status < 1,
- •7) Serum lactate dehydrogenase (LDH) < 1,1 x ULN,
- •8) At least 4 weeks since major prior surgery,
- •9) QTc interval duration < 430 ms for men, < 450 ms for women,
- •10) Adequate bone marrow, hepatic and renal function as follows:
- •- Lymphocytes > ou = 0.9 109/L
- •- Platelets > ou 100 x 109/L,
- •- Total bilirubin < ou = 2 x upper limit normal (ULN)
- •- Transaminases (AST [SGOT]; ALT SGPT]) < ou = 3 x ULN
- •- Serum creatinine < ou = 2.0 mg/dL or calculated creatinine clearance > 60mL/min;
- •11) Male or female patient who accepts and is able to use recognised highly effective contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly, or surgically sterile) throughout the study and during 3 months after the end of treatment;
- •12) Signed informed consent prior to any protocol-specific procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Primary ocular or mucosal melanoma;
- •2) Presence of any brain metastasis;
- •3) Concurrent treatment with any other anti-cancer therapy or any forbidden concomitant treatments;
- •4) Participation in another clinical trial with any investigative drug within 30 days prior to study randomization;
- •5) Prior history of high dose chemotherapy followed by bone marrow or peripheral stem cell support or presence of transplanted solid organ (with the exception of corneal transplant > 3 months prior to study randomization);
- •6) Any known hypersensitivity to one of the study treatments;
- •7) Any active auto-immune disease including the insulin-dependent diabetes or an immunodeficiency. The vitiligo is not an exclusion criterion;
- •8) Current active infection on the day of inclusion and judged serious by the investigator including viral infection HIV, HCV, HBV (HBsAg);
- •9) Serious concurrent, uncontrolled medical disorder such as diabetes;
- •10) Cardiovascular disease:
- •-Stage III or IV congestive heart failure (CHF) as determined by the New York Heart Association (NYHA) classification system for heart failure. Note: patients with NYHA stage I or II CHF may be included provided they do not have arrhythmia requiring treatment or fulfil any other exclusion criteria;
- •-Myocardial infarction within the previous 6 months, or
- •-Symptomatic cardiac arrhythmia requiring treatment;
- •11) History of another malignancy within the past 5 years, except basal cell carcinoma of the skin or carcinoma in situ of the cervix;
- •12) Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed with the patient before request for randomization in the trial;
- •13) Pregnant or lactating women.
研究者
相似试验
进行中（未招募）
不适用
A Phase II open label randomized parallel group non comparative trial to assess efficacy and safety of the association of IPH1101 and IL-2 alone and in combination with dacarbazine, in patients with metastatic melanomaEUCTR2007-007265-20-FRInnate Pharma50
进行中（未招募）
1 期
A trial to assess whether the new drug ATL1103 is safe and effective in patients who have acromegalyAcromegalyEUCTR2012-003147-30-GBAntisense Therapeutics Ltd30
进行中（未招募）
不适用
A trial to assess whether the new drug ATL1103 is safe and effective in patients who have acromegalyMedDRA version: 16.0Level: PTClassification code 10000599Term: AcromegalySystem Organ Class: 10014698 - Endocrine disordersAcromegalyEUCTR2012-003147-30-HUAntisense Therapeutics Ltd30
已完成
不适用
A Phase II Randomised, Open-Label, Parallel Group Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Two Subcutaneous Dosing Regimens of ATL1103 in Adult Patients with Acromegaly.Metabolic and Endocrine - Other metabolic disordersAcromegalyACTRN12612000989842Antisense Therapeutics Limited24
进行中（未招募）
不适用
A trial to assess whether the new drug ATL1103 is safe and effective in patients who have acromegalyAcromegalyEUCTR2012-003147-30-ESAntisense Therapeutics Ltd30